CTLA4 and neoplasm: In a spontaneously metastasizing immunologically “cold” model of early-stage NSCLC, we report that the combination of anti-CTLA-4 and BEMPEG inhibits the development of distant metastases and effectively eradicates IV injected tumor cells representing micro-metastatic disease.